Medpace: Six Insiders Sell $84M Above Analyst Target
Six Medpace insiders, including CEO Troendle, sold $84.29 million in shares since late July at prices between $585 and $625, all above the $581.83 analyst consensus target, with zero purchases in the
Medpace Insiders Sell $84M as Stock Tops Analyst Target
NEW YORK, August 26 —
Medpace Holdings, Inc. (MEDP) has delivered four consecutive earnings beats and 17.2% revenue growth, and its CEO, CFO, two directors, and EVP of Operations collectively sold $84.29 million in shares since late July, every trade above the $581.83 analyst consensus price target. When the people running the business sell above what the sell-side will defend, valuation becomes pointed.
- Six insiders, including CEO Troendle, sold $84.29 million in stock since late July; zero purchases in the same period.
- Every transaction priced between $585 and $625 per share, above the $581.83 sell-side consensus target.
- Trailing revenue hit $2.78 billion, up 17.2%; free cash flow $510 million; gross margin 72.4%.
Above the Target, With Zero Purchases
The pattern is hard to read as routine. Troendle, chief executive, executed a single trade of 27,174 shares at $618.79 on August 20, per regulatory filings, one of several transactions between $585 and $625 by five other insiders since late July, all above the sell-side consensus, with zero purchases in the same period. Medpace manages Phase I through Phase IV clinical trials for pharmaceutical, biotechnology, and medical device companies from its Cincinnati, Ohio headquarters; insiders collectively still hold 19.5% of shares outstanding after the selling. The collective timing is what narrows the interpretive window.
What 31.8x Is Buying
The underlying economics are genuinely strong: 72.4% gross margins, $753 million in operating cash flow, and $510 million in free cash flow reflect the capital-light nature of a contract research organization that runs clinical trials without manufacturing a single drug. Surprise margins running from 6.2% to 10.4% across four quarters have pushed trailing revenue to $2.78 billion. At $614.06 and 31.8x forward earnings, a level worth pressure-testing in the DCF calculator, the stock has priced in most of what consistent beats could reasonably buy. Whether those beats represent a lasting structural advantage or a favorable patch is precisely what the insiders are voting on.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| MEDP | $17.1B | 31.8x | +31.0% |
| KNSL | $8.8B | 17.9x | -12.3% |
| IQV | $42.7B | 17.9x | +38.6% |
| ICLR | $13.0B | 14.2x | -0.3% |
| LNTH | $6.6B | 16.0x | +77.3% |
| SAIA | $9.2B | 24.4x | +13.6% |
The Quarter That Settles It
The Q3 2026 earnings report is the first checkpoint. If Medpace sustains a beat in the 6%-plus range and raises full-year guidance, the insiders' timing looks like rational monetization after a hard-earned re-rating. If the beat compresses or revenue growth slows from the 17.2% trailing pace, the selling pattern will look more prescient. At 31.8x forward earnings with the stock already above analyst consensus and 7.1% short interest signaling a contingent positioned for disappointment, there is limited margin for error. Run the free Medpace Holdings, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why are Medpace insiders selling stock?
The article does not cite a stated reason for the selling. Six insiders, including CEO Troendle and the CFO, collectively sold $84.29 million since late July at prices between $585 and $625, all above the $581.83 sell-side consensus target, with zero purchases in the same period. Insiders still hold 19.5% of shares outstanding after the transactions.
How much have Medpace insiders sold in 2026?
Six insiders have sold a combined $84.29 million in shares since late July. CEO Troendle alone executed a single trade of 27,174 shares at $618.79 on August 20, and five other insiders transacted in the same $585 to $625 price range.
What is Medpace's revenue growth rate?
Medpace's trailing revenue reached $2.78 billion, up 17.2%, with earnings surprise margins ranging from 6.2% to 10.4% across four consecutive quarterly beats. Free cash flow stood at $510 million and gross margin at 72.4%.
Is Medpace stock above its analyst price target?
Yes. Every insider transaction since late July priced between $585 and $625, above the $581.83 sell-side consensus price target. At $614.06, the stock trades at 31.8x forward earnings with 7.1% short interest.
What should investors watch in Medpace Q3 earnings?
The Q3 2026 report is the first checkpoint. A beat of 6% or more with a full-year guidance raise would support rational monetization as the interpretation of the selling. A compressed beat or deceleration from the 17.2% trailing revenue growth rate would make the insider timing look more prescient.
Medpace Holdings CEO August Troendle and five other insiders have sold a combined $84.29 million of stock since late July, with Troendle's single largest trade — 27,174 shares at $618.79 on August 20 — executed well above the analyst consensus price target of $581.83. The selling spree follows four consecutive quarters of earnings beats, making insider timing the central question.